LT3687558T - Metaboliniai biožymenys, skirti atsako į fgf-18 junginį numatymui - Google Patents

Metaboliniai biožymenys, skirti atsako į fgf-18 junginį numatymui

Info

Publication number
LT3687558T
LT3687558T LTEPPCT/EP2018/076395T LTEP2018076395T LT3687558T LT 3687558 T LT3687558 T LT 3687558T LT EP2018076395 T LTEP2018076395 T LT EP2018076395T LT 3687558 T LT3687558 T LT 3687558T
Authority
LT
Lithuania
Prior art keywords
fgf
predicting response
metabolic biomarkers
biomarkers
metabolic
Prior art date
Application number
LTEPPCT/EP2018/076395T
Other languages
English (en)
Inventor
Christoph H. Ladel
Hans Guehring
Anne-Christine BAY-JENSEN
Morten Karsdal
Per Qvist
Original Assignee
Merck Patent Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Patent Gmbh filed Critical Merck Patent Gmbh
Publication of LT3687558T publication Critical patent/LT3687558T/lt

Links

Classifications

    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6887Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids from muscle, cartilage or connective tissue
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18Growth factors; Growth regulators
    • A61K38/1825Fibroblast growth factor [FGF]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/04Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475Growth factors; Growth regulators
    • C07K14/50Fibroblast growth factor [FGF]
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/78Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin or cold insoluble globulin [CIG]
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/78Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin, cold insoluble globulin [CIG]
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00Detection or diagnosis of diseases
    • G01N2800/10Musculoskeletal or connective tissue disorders
    • G01N2800/105Osteoarthritis, e.g. cartilage alteration, hypertrophy of bone
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00Detection or diagnosis of diseases
    • G01N2800/52Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Organic Chemistry (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Food Science & Technology (AREA)
  • Pathology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • General Physics & Mathematics (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Cell Biology (AREA)
  • Toxicology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Peptides Or Proteins (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
LTEPPCT/EP2018/076395T 2017-09-29 2018-09-28 Metaboliniai biožymenys, skirti atsako į fgf-18 junginį numatymui LT3687558T (lt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP17194220 2017-09-29
EP18169324 2018-04-25
PCT/EP2018/076395 WO2019063758A1 (en) 2017-09-29 2018-09-28 METABOLIC BIOMARKERS FOR PREDICTING RESPONSE TO FGF-18 COMPOUND

Publications (1)

Publication Number Publication Date
LT3687558T true LT3687558T (lt) 2022-06-27

Family

ID=63722380

Family Applications (1)

Application Number Title Priority Date Filing Date
LTEPPCT/EP2018/076395T LT3687558T (lt) 2017-09-29 2018-09-28 Metaboliniai biožymenys, skirti atsako į fgf-18 junginį numatymui

Country Status (16)

Country Link
US (2) US11513128B2 (lt)
EP (1) EP3687558B1 (lt)
JP (2) JP7791649B2 (lt)
CN (1) CN111163791A (lt)
AU (1) AU2018343982B2 (lt)
CA (1) CA3076029A1 (lt)
DK (1) DK3687558T3 (lt)
ES (1) ES2918250T3 (lt)
HR (1) HRP20220760T1 (lt)
HU (1) HUE058786T2 (lt)
IL (1) IL273613B2 (lt)
LT (1) LT3687558T (lt)
PL (1) PL3687558T3 (lt)
RS (1) RS63293B1 (lt)
SI (1) SI3687558T1 (lt)
WO (1) WO2019063758A1 (lt)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2016211950A1 (en) 2015-01-29 2017-07-13 Ares Trading S.A. Immunoassays for high positively charged proteins
IL273613B2 (en) 2017-09-29 2026-02-01 Merck Patent Gmbh Metabolic biomarkers for predicting response to FGF-18 compound
SI3688468T1 (sl) 2017-09-29 2022-08-31 Merck Patent Gmbh Vnetni biomarkerji za predvidevanje odzivov na spojino FGF-18
IL281333B2 (en) 2018-09-10 2025-11-01 Merck Patent Gmbh A method for reducing risk in a clinical trial

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2339002A1 (en) 1996-10-16 2011-06-29 ZymoGenetics, Inc. Fibroblast growth factor homologs
ES2493840T3 (es) 2002-10-07 2014-09-12 Zymogenetics, Inc. Procedimiento de administración de FGF-18
AU2003287697A1 (en) 2002-11-08 2004-06-03 Barnes-Jewish Hospital Uncoupled collagen synthesis and degradation assays
AU2005314438B2 (en) 2004-12-10 2012-03-29 Zymogenetics, Inc. FGF18 production in prokaryotic hosts
US8224579B2 (en) * 2005-06-17 2012-07-17 The Brigham And Women's Hospital, Inc. Method of diagnosing osteoarthritis
US20070292982A1 (en) 2006-06-16 2007-12-20 Jeffery Gail Holloway Method for Manufacturing Transparent Windows in Molded Semiconductor Packages
HRP20120643T1 (hr) 2006-08-25 2012-08-31 Ares Trading S.A. Liječenje poremećaja hrskavice sa fgf-18
JP2009257842A (ja) 2008-04-14 2009-11-05 Ttc:Kk 変形性関節症の検査方法及び診断用キット
JP5762282B2 (ja) 2008-05-02 2015-08-12 インタールーキン ジェネティクス, インコーポレイテッド 変形性関節症に関連する状態に対する遺伝的素因の検出
US20090299769A1 (en) 2008-05-29 2009-12-03 Nordic Bioscience Imaging A/S Prognostic osteoarthritis biomarkers
US20120115137A1 (en) 2010-08-31 2012-05-10 Kornman Kenneth S Methods of Predicting Osteoarthritis
TWI527590B (zh) 2011-06-17 2016-04-01 艾瑞斯貿易公司 Fgf-18之凍乾調配物
AU2013301607B2 (en) 2012-08-06 2018-10-18 Merck Patent Gmbh Prognosis biomarkers in cartilage disorders
CN104736723B (zh) * 2012-08-06 2017-10-31 默克专利有限公司 用于预测对fgf‑18化合物的响应性的遗传标记
US9829493B2 (en) * 2013-07-15 2017-11-28 Steven J. Svoboda Methods and apparatus for assessment of risk for joint injury
CA2931978A1 (en) 2013-12-02 2015-06-11 Abbvie Inc. Compositions and methods for treating osteoarthritis
ES2806026T3 (es) 2013-12-24 2021-02-16 Ares Trading Sa Formulación de FGF-18 en hidrogeles de alginato/colágeno
KR102622290B1 (ko) 2013-12-24 2024-01-05 아레스 트레이딩 에스.아. 크실로글루칸 겔 중의 fgf-18 제형물
HUE040350T2 (hu) 2014-02-20 2019-03-28 Merck Patent Gmbh FGF-18 vegyületadagoló étrend
MX2016010873A (es) 2014-02-20 2016-11-17 Merck Patent Gmbh Factor de crecimiento de fibroblastos 18 en los procedimientos para el trasplante de injertos y para ingenieria de tejidos.
JP6510547B2 (ja) 2014-02-20 2019-05-08 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツングMerck Patent Gesellschaft mit beschraenkter Haftung Fgf−18を含むインプラント
AU2016211950A1 (en) 2015-01-29 2017-07-13 Ares Trading S.A. Immunoassays for high positively charged proteins
MX380092B (es) 2015-11-06 2025-03-11 Samumed Llc Tratamiento de la osteoartritis.
US9983214B2 (en) 2016-04-15 2018-05-29 Esm Technologies, Llc Method for evaluating articular joint therapeutics
SI3688468T1 (sl) 2017-09-29 2022-08-31 Merck Patent Gmbh Vnetni biomarkerji za predvidevanje odzivov na spojino FGF-18
IL273613B2 (en) * 2017-09-29 2026-02-01 Merck Patent Gmbh Metabolic biomarkers for predicting response to FGF-18 compound
IL281333B2 (en) 2018-09-10 2025-11-01 Merck Patent Gmbh A method for reducing risk in a clinical trial

Also Published As

Publication number Publication date
EP3687558A1 (en) 2020-08-05
JP2020535436A (ja) 2020-12-03
US12332251B2 (en) 2025-06-17
AU2018343982A1 (en) 2020-04-09
US20230251271A1 (en) 2023-08-10
HUE058786T2 (hu) 2022-09-28
US20210231681A1 (en) 2021-07-29
JP7791649B2 (ja) 2025-12-24
WO2019063758A1 (en) 2019-04-04
AU2018343982B2 (en) 2025-03-27
EP3687558B1 (en) 2022-03-16
DK3687558T3 (da) 2022-06-20
PL3687558T3 (pl) 2022-07-18
RS63293B1 (sr) 2022-06-30
ES2918250T3 (es) 2022-07-14
CN111163791A (zh) 2020-05-15
JP2024105273A (ja) 2024-08-06
HRP20220760T1 (hr) 2022-09-02
IL273613A (en) 2020-05-31
CA3076029A1 (en) 2019-04-04
IL273613B2 (en) 2026-02-01
US11513128B2 (en) 2022-11-29
SI3687558T1 (sl) 2022-08-31
IL273613B1 (en) 2025-10-01

Similar Documents

Publication Publication Date Title
CY2025001I1 (el) Νεα αντι-pd-l1 αντισωματα
IL267797B1 (en) Anti-gpc3 antibody
EP3619955A4 (en) ACCESS CONTROL MECHANISM
DK3368060T3 (da) Glugacon-receptor-agonister
CL2020000951A1 (es) Célula.
DK3356411T3 (da) Bispecifikke antistoffer, der er specifikke for PD1 og TIM3
DK3344654T3 (da) Anti-lag-3-antistoffer
DK3350218T3 (da) Polyomavirus-neutraliserende antistoffer
IL256099A (en) Antibody
DK3657339T3 (da) Datacaching
EP2989096A4 (en) SUBSTITUTED 5- (3,5-DIMETHYLIZOXAZOLE-4-YL-) INDOLIN-2-ONE
DK3250593T3 (da) Anti-transthyretin-antistoffer
DK3481964T3 (da) Biomarkører for inflammatorisk tarmsygdom
EP3286210C0 (en) T CELL RECEPTOR
MA43957A (fr) Biomarqueurs de copanlisib
HUE048088T2 (hu) Új, netrin-1 elleni ellenanyag
PL3655420T3 (pl) Chromatografia
CL2015002973A1 (es) Ánodos compuestos recubiertos.
MA43958A (fr) Biomarqueurs copanlisib
IL257368A (en) Antibody
DK3253906T3 (da) Elektrolyt til elektroplettering
EP3328301A4 (en) POSTOPERATIVE FORECAST
LT3687558T (lt) Metaboliniai biožymenys, skirti atsako į fgf-18 junginį numatymui
IL273574A (en) Inflammatory biomarkers for predicting response to FGF-18 compound
LT3253749T (lt) Junginiai, pasižymintys priešnavikiniu aktyvumu